A review of Genentech's (NYSE: DAN) Q3 2008 earnings.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…

Roche Holding has offered to buy the rest of Genentech, about a 44% stake it doesn't already own, for $89 a share, or about $43.7 billion.

The deal would mark one of the Swiss drug maker's biggest acquisitions and would mean about $750 million to $850 million in pre-tax savings.

Earnings season provide traders with great opportunities to make big money as earnings news tends to make stocks move sharply. Here's a way to make big money trading options on stocks that are about to release earnings.

The author discusses the hot biotech stocks you don't want to miss based on the companies Gene Marcial introduced in his book "7 Commandments of Stock Investing". He talks about the company background and its rational behind its attraction.